I. MODIFIED AGREEMENTS
Biotech Co.*
(Country; Symbol) 		Pharma Co.
(Country) 		Change from original agreement Terms/Details (Date)
Andromeda Biotech Ltd. (subsidiary of Clal Biotechnology Industries Ltd.; Israel; TASE:CBI) Teva Pharmaceutical Industries Ltd. (Israel) Amended agreement to license worldwide rights to Phase III diabetes drug DiaPep277 from Andromeda Teva will invest $50M in Andromeda; it will have 60 days following an interim analysis of the ongoing Phase III DiaPep277 trial to invest $17.5M at a $90M pre-money valuation, and will invest an additional $17.5M at a $170M pre-money valuation, as well as $15M at an undisclosed point in time; Teva also will pay Andromeda royalties and will make additional payments if DiaPep277 is developed for other indications (12/3)
Exelixis Inc. (EXEL) GlaxoSmithKline plc (UK) Licensing agreement for the first of three possible options as part of a 2002 deal GSK gains exclusive rights to XL880, a small molecule for kidney, gastric and head and neck cancers; Exelixis will receive a $35M selection milestone; upon successful commercialization, Exelixis would receive double-digit royalties on product sales and will retain certain co-promotion rights in North America (12/14)
Targacept Inc. (TRGT) AstraZeneca plc (UK) Agreement under which AstraZeneca paid $2M to secure an option to license TC-5619 under the terms of the companies' December 2005 partnership Targacept will develop TC-5619 independently through Phase II, at which point AstraZeneca can license it for $40M up front, $226M in milestones and royalties (11/5)
II. TERMINATED AGREEMENTS
BioMarin Pharmaceutical Inc. (BMRN) Merck Serono (division of Merck KGaA; Germany) BioMarin reacquired the Canadian rights for tetra-hydrobiopterin (BH4), including Kuvan (sapropterin) Kuvan is an oral small molecule for the treatment of phenylketonuria developed in partnership with Merck Serono (12/18)
Genelabs Technologies Inc. (GNLB) Mitsubishi Tanabe Pharma Corp. (Japan) Terminated agreement for the lupus drug Prestara The 2004 agreement had given Tanabe responsibility for all development work and obtaining regulatory approval in Japan (11/19)
Maxygen Inc. (MAXY) F. Hoffmann-La Roche Ltd. (Switzerland) Terminated agreement for the development of MAXY-alpha (R7025), a pegylated interferon-alpha product for hepatitis B and hepatitis C Rights will return to Maxygen; Roche placed a hold on the program after Phase Ia data showed lower drug levels in serum than expected (11/26)
Nastech Pharmaceutical Co. Inc. (NSTK) Procter & Gamble Pharmaceuticals Inc. Terminated partnership to develop and commercialize a nasally administered form of parathyroid hormone to treat osteoporosis Nastech has reacquired the rights to teriparatide nasal spray; the original deal would have garnered Nastech about $600M
Notes:

# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market. TASE = Tel Aviv Stock Exchange.